

# **IMPLICACIONES CLÍNICAS DE LA LESIÓN RENAL AGUDA, SU RELACIÓN CON EL GRUPO ETARIO Y LA MORTALIDAD EN ADULTOS CRÍTICAMENTE ENFERMOS CON INFECCIÓN POR SARS-COV-2 DURANTE EL AÑO 2021**

**Jorge Luis Acosta Muñoz**  
Código estudiantil: 2023115250550

Trabajo de Investigación presentado como requisito para optar el título de:  
**Especialista en Nefrología**

**Tutores:**

**Carlos Guido Musso**  
MD | Spc. Médico Internista | Nefrología

**Mauricio Aldana Roa**  
MD | Spc. Cirujano General | Intensivista

**Henry J Gonzalez-Torres**  
Bio | Spc App Stat | MSc Bio (GenPop) | PhD (c) BioMed

## RESUMEN

La lesión renal aguda es una manifestación grave en pacientes con COVID-19. En pacientes hospitalizados con SARS-CoV-2 la incidencia alcanza hasta el 16%. Su presencia se relaciona a un marcador de gravedad de la enfermedad y un factor pronóstico negativo para la supervivencia de los pacientes que ingresan a la unidad de cuidados intensivos. **Objetivo:** El objetivo de nuestro trabajo fue evaluar las implicaciones clínicas de la lesión renal aguda, su relación con el grupo etario y la mortalidad en adultos críticamente enfermos con infección por SARS-CoV-2. **Materiales y métodos:** Esta investigación fue de tipo analítico, correlacional, retrospectivo. Se incluyó pacientes mayores de 18 años con neumonía por SARS-CoV-2, ingresados a la unidad de cuidados intensivos en Barranquilla (Colombia) entre enero y diciembre del año 2021. Se dividieron según la presencia de lesión renal aguda y se caracterizó acorde a la edad. Según el grupo etario los pacientes se dividieron en pacientes adultos (21 – 44 años), adultos de edad mediana (45 – 65 años) y adultos de edad avanzada (>65 años). Los datos se evaluaron mediante regresión logística univariada. La mortalidad se determinó a través cocientes de riesgos instantáneos (HR) con intervalos de confianza al 95%. **Resultados:** Se incluyeron 199 pacientes. La presencia de lesión renal aguda fue 59.8%. Al evaluar la prevalencia de la lesión renal aguda según los grupos etarios, se observa que el 18.5% (n = 22) corresponde a pacientes entre 21 - 44 años, el 42.9% (n = 51) entre 45 – 65 años y el 38.7% (n = 46) >65 años. En nuestros resultados, no se encontraron pacientes entre edades de 18 a 20 años con neumonía por SARS-CoV-2 admitidos a la unidad de cuidados intensivos. Según la clasificación KDIGO de LRA el estadio III fue el más predominante en los grupos estadios evaluados (21 – 44 años [n =54.5%], 45 – 65 años [54.9%] y >65 años [69.6%]). Los pacientes con lesión renal aguda presentaron APACHE II elevado, presencia de diabetes mellitus (27.6%), necesidad de ventilación mecánica invasiva (75.4%), aminas vasoactivas y altos niveles de ferritina y lactato deshidrogenasa. La presencia de lesión renal aguda no influyó en un riesgo de mortalidad (HR = 1.73: IC 95% [1.12 – 2.68]; p = 0.013). **Conclusiones:** En este estudio retrospectivo encontramos una alta

incidencia de lesión renal aguda que afectó con más frecuencia a pacientes con edades entre 45 – 65 años hospitalizados con neumonía grave por SARS-CoV-2. La presencia de APACHE II elevado, condiciones clínicas como la diabetes mellitus, enfermedad renal crónica, la necesidad de ventilación mecánica invasiva, vasoactivo o inotrópicos tuvo un impacto en la presencia de lesión renal aguda. Además, se encontró que niveles elevados de ferritina, lactato deshidrogenasa, creatinina sérica y nitrógeno ureico a la admisión se asociaron estadísticamente con la presencia de lesión renal aguda. No obstante, al evaluar los grupos etarios, y la presencia de lesión renal aguda no influyó con la mortalidad durante el curso de la hospitalización.

**Palabras clave:** Lesión renal aguda; grupo etario; SARS-CoV-2; Críticamente enfermos.

## ABSTRACT

Acute kidney injury is a severe manifestation in patients with COVID-19. In hospitalized patients with SARS-CoV-2, the incidence reaches up to 16%. Its presence is related to a marker of disease severity and a negative prognostic factor for the survival of patients admitted to the intensive care unit. **Objective:** The objective of our work was to evaluate the clinical implications of acute kidney injury, its relationship with age group, and mortality in critically ill adults with SARS-CoV-2 infection. **Materials and methods:** This research was analytical, correlational, and retrospective. Patients over 18 years of age with SARS-CoV-2 pneumonia admitted to the intensive care unit in Barranquilla (Colombia) between January and December 2021 were included. They were divided according to the presence of acute kidney injury and characterized according to age. According to the age group, patients were divided into adult patients (21-44 years), middle-aged adults (45-65 years), and elderly adults (>65 years). Data were evaluated by univariate logistic regression. Mortality was determined through hazard ratios (HR) with 95% confidence intervals.

**Results:** 199 patients were included. The presence of acute kidney injury was 59.8%. When evaluating the prevalence of acute kidney injury according to age groups, it is observed that 18.5% (n = 22) corresponds to patients between 21 - 44 years, 42.9% (n = 51) between 45 - 65 years, and 38.7% (n = 46) >65 years. In our results, no patients between the ages of 18 and 20 years with SARS-CoV-2 pneumonia admitted to the intensive care unit were found. According to the KDIGO classification of AKI, stage III was the most predominant in the evaluated stage groups (21 – 44 years [n = 54.5%], 45 – 65 years [54.9%], and >65 years [69.6%]). Patients with acute kidney injury had elevated APACHE II, the presence of diabetes mellitus (27.6%), the need for invasive mechanical ventilation (75.4%), vasoactive amines, and high levels of ferritin and lactate dehydrogenase. The presence of acute kidney injury did not influence the mortality risk (HR = 1.73: 95% CI [1.12 – 2.68]; p = 0.013). **Conclusions:** In this retrospective study, we found a high incidence of acute kidney injury that more frequently affected patients between the ages of 45 – 65 years hospitalized with severe SARS-CoV-2 pneumonia. The presence of elevated APACHE II, clinical conditions such as diabetes mellitus, CKD, the need for invasive mechanical ventilation, and vasoactive or inotropic agents had an impact on the presence of acute kidney injury. In addition, elevated levels of ferritin, lactate dehydrogenase, serum creatinine, and urea nitrogen on admission were statistically associated with acute kidney injury. However, when evaluating the age groups, the presence of acute kidney injury did not influence mortality during hospitalization.

**Key Words:** Acute kidney injury; age groups; SARS-CoV-2; critically ill

## REFERENCIAS BIBLIOGRÁFICAS

1. Martín de Francisco Á, Fernández Fresnedo G. Enfermedad renal en la COVID-19 persistente: un objetivo inmediato para Nefrología. *Nefrología*. 2023 Jan;43(1):1–5. Available from: <https://doi.org/10.1016/j.nefro.2022.04.004>
2. Li Q, Guan X, Wu P, Wang X, Zhou L, Tong Y, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus–Infected Pneumonia. *N Engl J Med*. 2020 Mar 26;382(13):1199–207. Available from: <https://doi.org/10.1056/NEJMoa2001316>
3. Salazar-Martínez E, Hernández-Mariano JÁ, Galván-Portillo M, Baltazar-Reyes MC, Parra-Cabrera MS, Tamayo y Orozco JA, et al. Marcadores de funcionamiento renal en pacientes infectados por SARS-CoV-2. Revisión rápida de la literatura. *Salud Publica Mex*. 2021 Jan 14;63(2, Mar–Abr):253–61. Available from: <https://doi.org/10.21149/11918>
4. Chan L, Chaudhary K, Saha A, Chauhan K, Vaid A, Zhao S, et al. AKI in Hospitalized Patients with COVID-19. *J Am Soc Nephrol*. 2021 Jan;32(1):151–60. Available from: <https://doi.org/10.1681/ASN.2020050615>
5. Menter T, Haslbauer JD, Nienhold R, Savic S, Hopfer H, Deigendesch N, et al. Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. *Histopathology*. 2020 Aug 5;77(2):198–209. Available from: <https://doi.org/10.1111/his.14134>
6. Sawhney S, Fraser SD. Epidemiology of AKI: Utilizing Large Databases to Determine the Burden of AKI. *Adv Chronic Kidney Dis*. 2017 Jul;24(4):194–204. Available from: <https://dx.doi.org/10.1053/j.ackd.2017.05.001>
7. Hoste EAJ, Kellum JA, Selby NM, Zarbock A, Palevsky PM, Bagshaw SM, et al. Global epidemiology and outcomes of acute kidney injury. *Nat Rev Nephrol*. 2018 Oct 22;14(10):607–25. Available from: <https://dx.doi.org/10.1038/s41581-018-0052-0>
8. McMahon BA, Koyner JL. Risk Stratification for Acute Kidney Injury: Are Biomarkers Enough? *Adv Chronic Kidney Dis*. 2016 May;23(3):167–78. Available from: <https://dx.doi.org/10.1053/j.ackd.2016.03.001>
9. Algarín-Lara H, Guevara-Romero E, Osorio-Rodríguez E, Patiño-Patiño J, Flórez García V, Tuesca R de J, et al. Factores relacionados con la neumonía bacteriana en pacientes con COVID-19 en una unidad de cuidados intensivos de Barranquilla, Colombia. *Acta Colomb Cuid Intensivo*. 2022 Jun;22:S28–35. Available from: <https://doi.org/10.1016/j.acci.2021.07.002>
10. Organización Panamericana de la Salud. Monthly COVID-19 Epidemiological Update - Region of the Americas - 02 August 2023. Organización Panamericana de la Salud. 2023. p. 1–10. Available from:

<https://www.paho.org/en/documents/monthly-covid-19-epidemiological-update-region-americas-02-august-2023>

11. Osorio-Rodríguez E, Aldana-Roa M, Patiño-Patiño JJ, Rodado-Villa R, Ariza-Miranda L, Aldana-Roa JD, et al. Sobreinfecciones intrahospitalarias y su relación con la mortalidad en pacientes obesos o diabéticos con COVID-19 críticamente enfermos. *Acta Colomb Cuid Intensivo*. 2024 Jan; Available from: <https://doi.org/10.1016/j.acci.2023.12.002>

12. Algarín-Lara H, Osorio-Rodríguez E, Patiño-Patiño J, Mendoza-Morales I, Rodado-Villa R. Neumonía por SARS-CoV-2 asociado a coinfección por *Pneumocystis jirovecii* en paciente inmunocomprometido: a propósito de un caso y revisión de la literatura. *Acta Colomb Cuid Intensivo*. 2022 Jun;22:S106–13. Available from: <https://doi.org/10.1016/j.acci.2021.07.001>

13. Algarín-Lara H, Rudas Moscarella JM, Aldana-Roa J, Patiño-Patiño J, Sajona-Nieves E, Aldana-Roa M, et al. Superinfección por *Stenotrophomonas maltophilia* en pacientes con COVID-19 críticamente enfermos. Análisis de una serie de casos. *Acta Colomb Cuid Intensivo*. 2022 Jun;22:S138–42. Available from: <https://doi.org/10.1016/j.acci.2021.08.001>

14. Algarín Lara H, Rodado Villa R, Aldana Roa MF, Osorio Rodríguez EL, Patiño Patiño JJ. Neumotórax espontáneo primario no asociado a ventilación mecánica invasiva en pacientes con neumonía por COVID-19. Presentación de 2 casos. *Acta Colomb Cuid Intensivo*. 2022 Apr;22(2):149–53. Available from: <https://doi.org/10.1016/j.acci.2021.03.002>

15. Algarin-Lara H, Osorio-Rodríguez E, Patiño-Patiño J, Solano-Roper J, Rodado-Villa R. Hipercapnia refractaria en paciente con síndrome de obesidad-hipoventilación maligno y COVID-19. Reporte de caso y propuesta de manejo. *Acta Colomb Cuid Intensivo*. 2022 Jun;22:S117–22. Available from: <https://doi.org/10.1016/j.acci.2021.09.005>

16. Moore PK, Hsu RK, Liu KD. Management of Acute Kidney Injury: Core Curriculum 2018. *Am J Kidney Dis*. 2018 Jul;72(1):136–48. Available from: <https://doi.org/10.1053/j.ajkd.2017.11.021>

17. Cheng Y, Luo R, Wang X, Wang K, Zhang N, Zhang M, et al. The Incidence, Risk Factors, and Prognosis of Acute Kidney Injury in Adult Patients with Coronavirus Disease 2019. *Clin J Am Soc Nephrol*. 2020 Oct 7;15(10):1394–402. Available from: <https://doi.org/10.2215/CJN.04650420>

18. Vargas JG, Avila N, Hurtado D, Cárdenas-Roldán J, Peña D, Ortiz G. Lesión renal aguda en COVID-19: puesta al día y revisión de la literatura. *Acta Colomb Cuid Intensivo*. 2022 Jan;22(1):24–34. Available from: <https://doi.org/10.1016/j.acci.2020.10.004>

19. Stockmann H, Hardenberg J-HB, Aigner A, Hinze C, Gotthardt I, Stier B, et al. High rates of long-term renal recovery in survivors of coronavirus disease 2019–

- associated acute kidney injury requiring kidney replacement therapy. *Kidney Int.* 2021 Apr;99(4):1021–2. Available from: <https://doi.org/10.1016/j.kint.2021.01.005>
20. Weber DJ, Rutala WA, Fischer WA, Kanamori H, Sickbert-Bennett EE. Emerging infectious diseases: Focus on infection control issues for novel coronaviruses (Severe Acute Respiratory Syndrome-CoV and Middle East Respiratory Syndrome-CoV), hemorrhagic fever viruses (Lassa and Ebola), and highly pathogenic avian influenza vi. *Am J Infect Control.* 2016 May;44(5):e91–100. Available from: <https://dx.doi.org/10.1016/j.ajic.2015.11.018>
21. Chilamakuri R, Agarwal S. COVID-19: Characteristics and Therapeutics. *Cells.* 2021 Jan 21;10(2):206. Available from: <https://doi.org/10.3390/cells10020206>
22. Fabrizi F, Nardelli L, Regalia A, Zanoni F, Castellano G. Are Kidneys Affected by SARS-CoV-2 Infection? An Updated Review on COVID-19-Associated AKI. *Pathogens.* 2024 Apr 16;13(4):325. Available from: <https://doi.org/10.3390/pathogens13040325>
23. Long B, Carius BM, Chavez S, Liang SY, Brady WJ, Koefman A, et al. Clinical update on COVID-19 for the emergency clinician: Presentation and evaluation. *Am J Emerg Med.* 2022 Apr;54:46–57. Available from: <https://doi.org/10.1016/j.ajem.2022.01.028>
24. Huang L, Li X, Gu X, Zhang H, Ren L, Guo L, et al. Health outcomes in people 2 years after surviving hospitalisation with COVID-19: a longitudinal cohort study. *Lancet Respir Med.* 2022 Sep;10(9):863–76. Available from: [https://doi.org/10.1016/S2213-2600\(22\)00126-6](https://doi.org/10.1016/S2213-2600(22)00126-6)
25. Ng JH, Hirsch JS, Hazzan A, Wanchoo R, Shah HH, Malieckal DA, et al. Outcomes Among Patients Hospitalized With COVID-19 and Acute Kidney Injury. *Am J Kidney Dis.* 2021 Feb;77(2):204–215.e1. Available from: <https://doi.org/10.1053/j.ajkd.2020.09.002>
26. Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM, et al. COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes. *Am J Epidemiol.* 2021 Jan 4;190(1):161–75. Available from: <https://doi.org/10.1093/aje/kwaa191>
27. Zhang Y, Li H, Zhang J, Cao Y, Zhao X, Yu N, et al. The clinical characteristics and outcomes of patients with diabetes and secondary hyperglycaemia with coronavirus disease 2019: A single-centre, retrospective, observational study in Wuhan. *Diabetes, Obes Metab.* 2020 Aug 17;22(8):1443–54. Available from: <https://doi.org/10.1111/dom.14086>
28. Rajpal A, Rahimi L, Ismail-Beigi F. Factors leading to high morbidity and mortality of COVID-19 in patients with type 2 diabetes. *J Diabetes.* 2020 Dec 2;12(12):895–908. Available from: <https://doi.org/10.1111/1753-0407.13085>

29. Radzikowska U, Ding M, Tan G, Zhakparov D, Peng Y, Wawrzyniak P, et al. Distribution of ACE2, CD147, CD26, and other SARS-CoV-2 associated molecules in tissues and immune cells in health and in asthma, COPD, obesity, hypertension, and COVID-19 risk factors. *Allergy*. 2020 Nov 24;75(11):2829–45. Available from: <https://doi.org/10.1111/all.14429>
30. Klok FA, Kruip MJHA, van der Meer NJM, Arbous MS, Gommers DAMPJ, Kant KM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thromb Res*. 2020 Jul;191:145–7. Available from: <https://doi.org/10.1016/j.thromres.2020.04.013>
31. Khwaja A. KDIGO Clinical Practice Guidelines for Acute Kidney Injury. *Nephron Clin Pract*. 2012 Aug 7;120(4):c179–84. Available from: <https://doi.org/10.1159/000339789>
32. Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. *Am J Nephrol*. 2020;51(5):343–8. Available from: <https://doi.org/10.1159/000507471>
33. Martinez-Rojas MA, Vega-Vega O, Bobadilla NA. Is the kidney a target of SARS-CoV-2? *Am J Physiol Physiol*. 2020 Jun 1;318(6):F1454–62. Available from: <https://doi.org/10.1152/ajprenal.00160.2020>
34. Legrand M, Bell S, Forni L, Joannidis M, Koyner JL, Liu K, et al. Pathophysiology of COVID-19-associated acute kidney injury. *Nat Rev Nephrol*. 2021 Nov 5;17(11):751–64. Available from: <https://doi.org/10.1038/s41581-021-00452-0>
35. Hamming I, Timens W, Bulthuis M, Lely A, Navis G, van Goor H. Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis. *J Pathol*. 2004 Jun 7;203(2):631–7. Available from: <https://doi.org/10.1002/path.1570>
36. Diao B, Wang C, Wang R, Feng Z, Zhang J, Yang H, et al. Human kidney is a target for novel severe acute respiratory syndrome coronavirus 2 infection. *Nat Commun*. 2021 May 4;12(1):2506. Available from: <https://doi.org/10.1038/s41467-021-22781-1>
37. Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. Kidney disease is associated with in-hospital death of patients with COVID-19. *Kidney Int*. 2020 May;97(5):829–38. Available from: <https://doi.org/10.1016/j.kint.2020.03.005>
38. Rabb H. Kidney diseases in the time of COVID-19: major challenges to patient care. *J Clin Invest*. 2020 May 11;130(6):2749–51. Available from: <https://doi.org/10.1172/JCI138871>
39. Zhang WR, Parikh CR. Biomarkers of Acute and Chronic Kidney Disease. *Annu Rev Physiol*. 2019 Feb 10;81(1):309–33. Available from: <https://doi.org/10.1146/annurev-physiol-020518-114605>

40. Razi O, Teixeira AM, Tartibian B, Zamani N, Knechtle B. Respiratory issues in patients with multiple sclerosis as a risk factor during SARS-CoV-2 infection: a potential role for exercise. *Mol Cell Biochem.* 2023 Jul 21;478(7):1533–59. Available from: <https://doi.org/10.1007/s11010-022-04610-1>
41. Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. *J Pharm Anal.* 2020;10(2):102–8. Available from: <https://doi.org/10.1016/j.jpha.2020.03.001>
42. Li G, Fan Y, Lai Y, Han T, Li Z, Zhou P, et al. Coronavirus infections and immune responses. *J Med Virol.* 2020 Apr 7;92(4):424–32. Available from: <https://doi.org/10.1002/jmv.25685>
43. Tisoncik JR, Korth MJ, Simmons CP, Farrar J, Martin TR, Katze MG. Into the Eye of the Cytokine Storm. *Microbiol Mol Biol Rev.* 2012 Mar;76(1):16–32. Available from: <https://doi.org/10.1128/MMBR.05015-11>
44. Ahmadian E, Hosseiniyan Khatibi SM, Razi Soofiyan S, Abediazar S, Shoja MM, Ardalan M, et al. Covid-19 and kidney injury: Pathophysiology and molecular mechanisms. *Rev Med Virol.* 2021 May 6;31(3). Available from: <https://doi.org/10.1002/rmv.2176>
45. Gupta A, Madhavan M V., Sehgal K, Nair N, Mahajan S, Sehrawat TS, et al. Extrapulmonary manifestations of COVID-19. *Nat Med.* 2020 Jul 10;26(7):1017–32. Available from: <https://doi.org/10.1038/s41591-020-0968-3>
46. Caicedo Mesa A, Méndez Fandiño YR, Larrotta Salamanca LX, Díaz Lache LL, Forero Alvarado MJ, Cortés Motta HF, et al. Pandemia de COVID-19 y enfermedad renal ¿qué sabemos actualmente? *Rev Colomb Nefrol.* 2020 Jul 16;7(1):23–4. Available from: <https://doi.org/10.22265/acnef.7.Supl.2.438>
47. Fisher M, Neugarten J, Bellin E, Yunes M, Stahl L, Johns TS, et al. AKI in Hospitalized Patients with and without COVID-19: A Comparison Study. *J Am Soc Nephrol.* 2020 Sep;31(9):2145–57. Available from: <https://doi.org/10.1681/ASN.2020040509>
48. Wang J, Wang Z, Zhu Y, Li H, Yuan X, Wang X, et al. Identify the Risk Factors of COVID-19-Related Acute Kidney Injury: A Single-Center, Retrospective Cohort Study. *Front Med.* 2020 Jul 28;7. Available from: <https://doi.org/10.3389/fmed.2020.00436>
49. Fominskiy E V., Scandroglio AM, Monti G, Calabrò MG, Landoni G, Dell'Acqua A, et al. Prevalence, Characteristics, Risk Factors, and Outcomes of Invasively Ventilated COVID-19 Patients with Acute Kidney Injury and Renal Replacement Therapy. *Blood Purif.* 2021;50(1):102–9. Available from: <https://doi.org/10.1159/000508657>
50. He W, Liu X, Hu B, Li D, Chen L, Li Y, et al. Gender and Ethnic Disparities of Acute Kidney Injury in COVID-19 Infected Patients: A Literature Review. *Front Cell*

Infect Microbiol. 2022 Jan 13;11. Available from:  
<https://doi.org/10.3389/fcimb.2021.778636>

51. Zhang J, Pang Q, Zhou T, Meng J, Dong X, Wang Z, et al. Risk factors for acute kidney injury in COVID-19 patients: an updated systematic review and meta-analysis. *Ren Fail.* 2023 Dec 31;45(1). Available from:  
<https://doi.org/10.1080/0886022X.2023.2170809>

52. Guan W, Ni Z, Hu Y, Liang W, Ou C, He J, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med.* 2020 Apr 30;382(18):1708–20. Available from: <https://doi.org/10.1056/NEJMoa2002032>

53. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. *Lancet.* 2020 Feb;395(10223):507–13. Available from: [https://doi.org/10.1016/S0140-6736\(20\)30211-7](https://doi.org/10.1016/S0140-6736(20)30211-7)

54. Wainstein M, MacDonald S, Fryer D, Young K, Balan V, Begum H, et al. Use of an extended KDIGO definition to diagnose acute kidney injury in patients with COVID-19: A multinational study using the ISARIC–WHO clinical characterisation protocol. Remuzzi G, editor. *PLOS Med.* 2022 Apr 20;19(4):e1003969. Available from: <https://doi.org/10.1371/journal.pmed.1003969>

55. Chávez-Íñiguez JS, Cano-Cervantes JH, Maggiani-Aguilera P, Lavelle-Góngora N, Marcial-Meza J, Camacho-Murillo EP, et al. Mortality and evolution between community and hospital-acquired COVID-AKI. Bikbov B, editor. *PLoS One* . 2021 Nov 4;16(11):e0257619. Available from: <https://doi.org/10.1371/journal.pone.0257619>

56. Contreras-Villamizar K, Barbosa O, Muñoz AC, Suárez JS, González CA, Vargas DC, et al. Risk factors associated with acute kidney injury in a cohort of hospitalized patients with COVID-19. *BMC Nephrol.* 2023 May 22;24(1):140. Available from: <https://doi.org/10.1186/s12882-023-03172-8>

57. Arenas CL, Forero ACP, Ángel DCV, López PMR, Diaz LVG, Aguilar DKN, et al. Risk factors for acute kidney injury in patients hospitalized with COVID-19. *Brazilian J Nephrol.* 2024 Jun;46(2). Available from: <https://doi.org/10.1590/2175-8239-JBN-2023-0056en>

58. OH TE, HUTCHINSON R, SHORT S, BUCKLEY T, LIN E, LEUNG D. Verification of the Acute Physiology and Chronic Health Evaluation scoring system in a Hong Kong intensive care unit. *Crit Care Med.* 1993 May;21(5):698–705. Available from: <https://doi.org/10.1097/00003246-199305000-00013>

59. Andrade Sierra J, Delgado Astorga C, Nava Vargas MG, Rojas Campos E, Arrelano Arteaga KJ, Hernández Morales K, et al. Procalcitonin and High APACHE (Acute Physiological and Chronic Health Evaluation) Level Are Associated with the Course of Acute Kidney Injury in Patients with SARS-CoV-2. Chen T-C, editor. *Int J*

Clin Pract. 2022 Oct 7;2022:1–9. Available from:  
<https://doi.org/10.1155/2022/1363994>

60. Kolhe N V., Fluck RJ, Selby NM, Taal MW. Acute kidney injury associated with COVID-19: A retrospective cohort study. Remuzzi G, editor. PLOS Med . 2020 Oct 30;17(10):e1003406. Available from:  
<https://doi.org/10.1371/journal.pmed.1003406>

61. See YP, Young BE, Ang LW, Ooi XY, Chan CP, Looi WL, et al. Risk Factors for Development of Acute Kidney Injury in COVID-19 Patients: A Retrospective Observational Cohort Study. Nephron. 2021;145(3):256–64. Available from:  
<https://doi.org/10.1159/000514064>

62. Cai X, Wu G, Zhang J, Yang L. Risk Factors for Acute Kidney Injury in Adult Patients With COVID-19: A Systematic Review and Meta-Analysis. Front Med. 2021 Dec 6;8. Available from: <https://doi.org/10.3389/fmed.2021.719472>

63. Hirsch JS, Ng JH, Ross DW, Sharma P, Shah HH, Barnett RL, et al. Acute kidney injury in patients hospitalized with COVID-19. Kidney Int. 2020 Jul;98(1):209–18. Available from: <https://doi.org/10.1016/j.kint.2020.05.006>

64. Pelayo J, Lo KB, Bhargav R, Gul F, Peterson E, DeJoy III R, et al. Clinical Characteristics and Outcomes of Community- and Hospital-Acquired Acute Kidney Injury with COVID-19 in a US Inner City Hospital System. Cardiorenal Med. 2020;10(4):223–31. Available from: <https://doi.org/10.1159/000509182>

65. Lombardi R, Ferreiro A, Ponce D, Claire-Del Granado R, Aroca G, Venegas Y, et al. Latin American registry of renal involvement in COVID-19 disease. The relevance of assessing proteinuria throughout the clinical course. Dass B, editor. PLoS One. 2022 Jan 27;17(1):e0261764. Available from:  
<https://doi.org/10.1371/journal.pone.0261764>

66. Petrucci N, De Feo C. Lung protective ventilation strategy for the acute respiratory distress syndrome. Cochrane Database Syst Rev. 2013 Feb 28; Available from: <https://doi.org/10.1002/14651858.CD003844.pub4>

67. Bullen A, Liu ZZ, Hepokoski M, Li Y, Singh P. Renal Oxygenation and Hemodynamics in Kidney Injury. Nephron. 2017;137(4):260–3. Available from:  
<https://doi.org/10.1159/000477830>

68. Casas-Aparicio GA, León-Rodríguez I, Alvarado-de la Barrera C, González-Navarro M, Peralta-Prado AB, Luna-Villalobos Y, et al. Acute kidney injury in patients with severe COVID-19 in Mexico. Burdmann EA, editor. PLoS One. 2021 Feb 8;16(2):e0246595. Available from: <https://doi.org/10.1371/journal.pone.0246595>

69. Denic A, Glassock RJ, Rule AD. Structural and Functional Changes With the Aging Kidney. Adv Chronic Kidney Dis. 2016 Jan;23(1):19–28. Available from:  
<https://doi.org/10.1053/j.ackd.2015.08.004>

70. Oliveira JE de, Santos TA dos, Belasco AGS, Barbosa DA, Santos ES, Góes Junior MA de, et al. Acute kidney injury and COVID-19 in young adults in intensive

care. Acta Paul Enferm. 2023 Oct 25;37. Available from:  
<https://doi.org/10.37689/acta-ape/2024AO0027511>

71. Lombardi R, Ferreiro A, Claire-Del Granado R, Burdmann EA, Rosa-Diez G, Yu L, et al. EPILAT-IRA Study: A contribution to the understanding of the epidemiology of acute kidney injury in Latin America. Lazzeri C, editor. PLoS One . 2019 Nov 14;14(11):e0224655. Available from:  
<https://doi.org/10.1371/journal.pone.0224655>

72. de Almeida DC, Franco M do CP, dos Santos DRP, Santos MC, Maltoni IS, Mascotte F, et al. Acute kidney injury: Incidence, risk factors, and outcomes in severe COVID-19 patients. Seguro AC, editor. PLoS One. 2021 May 25;16(5):e0251048. Available from: <https://doi.org/10.1371/journal.pone.0251048>